High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial
Posted inDiabetes & Endocrinology news Pediatrics

High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial

The POInT trial demonstrated that high-dose daily oral insulin does not prevent islet autoantibodies in infants at high genetic risk for type 1 diabetes. Despite its safety, the primary endpoint was not met, though genotype-specific interactions suggest a need for more personalized prevention strategies.
Factor XI Inhibition Redefined: Catalytic Domain Blockade Emerges as a Superior Strategy for VTE Prevention
Posted inHematology-Oncology news Orthopedics

Factor XI Inhibition Redefined: Catalytic Domain Blockade Emerges as a Superior Strategy for VTE Prevention

The ROXI-VTE trials demonstrate that inhibiting the Factor XI catalytic domain significantly reduces postoperative VTE compared to enoxaparin. While blocking Factor XIIa-mediated activation showed promise, it failed to meet superiority, highlighting the critical role of Factor XI's catalytic activity in surgical thromboprophylaxis.
Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?
Posted inDermatology news Rheumatology

Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?

The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, highlighting potential steroid-sparing benefits in early intervention.
Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis
Posted innews Orthopedics Rheumatology

Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis

The CLEAT trial demonstrates that an 8-week cycling and education program (CHAIN) significantly improves function in hip osteoarthritis compared to usual physiotherapy. Despite falling just short of the clinical importance threshold, its high cost-effectiveness positions it as a viable community-based alternative for the NHS.
Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial
Posted inInfectious Diseases news Respiratory

Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial

The Phase 2b PanACEA-DECODE-01 trial identifies delpazolid 1200 mg once daily as an effective and safer oxazolidinone alternative to linezolid, demonstrating a 38% faster mycobacterial load decline when added to a bedaquiline, delamanid, and moxifloxacin backbone for pulmonary tuberculosis treatment.
Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial
Posted inInfectious Diseases news Respiratory

Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial

The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression typical of linezolid, offering a promising alternative for drug-resistant TB therapy.
Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer
Posted innews Oncology Otorhinolaryngology Pathology & Lab Medicine

Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer

Research identifies postoperative lymphatic exudate as a superior source of ctDNA for detecting molecular residual disease in HPV-independent head and neck cancer. This proximal liquid biopsy significantly outperforms plasma in predicting locoregional recurrence and may refine adjuvant treatment decisions for intermediate-risk patients.